4. FEJEZET | HIVATKOZÁSOK

  1. Dunkley S, Lam JCM, John MJ, et al. Principles of haemophilia care: the Asia-Pacific perspective. Haemophilia. 2018;24(4):e243 -e244.
  2. Keeney S, Mitchell M, Goodeve A, UK Haemophilia Center Doctors’ Organization Haemophilia Genetics Laboratory Network. The molecular analysis of haemophilia A: a guideline from the UK Haemophilia Centre Doctors’ Organization Haemophilia Genetics Laboratory Network. Haemophilia 2005;11(4):387-397.
  3. Mitchell M, Keeney S, Goodeve A, UK Haemophilia Centre Doctors’ Organization Haemophilia Genetics Laboratory Network. The molecular analysis of haemophilia B: a guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network. Haemophilia 2005;11(4):398-404.
  4. Keeney S, Mitchell M, Goodeve A, UK Haemophilia Centre Doctors’ Organisation (UKHCDO), the Haemophilia Genetics Laboratory Network, and the Clinical Molecular Genetics Society. Practice Guidelines for the Molecular Diagnosis of Haemophilia A. UKHCDO and CMGS, 2010. https://pdfs.semanticscholar.org/0abb/cfa3a7bdc1516b704131050ccd0d5e5e14dd.pdf. Hozzáférés: 2020. február 8.
  5. Mitchell M, Keeney S, Goodeve A, on behalf of the UK Haemophilia Centre Doctors’ Organisation (UKHCDO), the Haemophilia Genetics Laboratory Network, and the Clinical Molecular Genetics Society, Practice Guidelines for the Molecular Diagnosis of Haemophilia B. UKHCDO and CMGS, 2010. https://www.acgs.uk.com/media/10771/haemophilia_b_bpg_revision_sept_2011_ approved.pdf. Hozzáférés: 2020. február 8.
  6. Gomez K, Laffan M, Keeney S, Sutherland M, Curry N, Lunt P. Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders: a UK Haemophilia Centre Doctors’ Organisation Good Practice Paper. Haemophilia. 2019;25(1):116-126.
  7. Genetics Working Party, United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). Clinical Genetics Services for Haemophilia. Ellenőrzés dátuma: 2018. május. Genetics Working Party, 2015. http://www.ukhcdo.org/wp-content/uploads/2015/12/ Guidelines_on_genetics_services_for_haemophilia_v5-3_1_final.pdf. Hozzáférés: 2020. áprili 28.
  8. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52-56.
  9. Sidonio RF, Mili FD, Li T, et al. Females with FVIII and FIX deficiency have reduced joint range of motion. Am J Hematol. 2014;89(8):831-836.
  10. James PD, Mahlangu J, Bidlingmaier C, et al. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016;22(6):912-918.
  11. Pavlova A, Brondke H, Musebeck J, Pollmann H, Srivastava A, Oldenburg J. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost. 2009;7(6):976-982.
  12. Radic CP, Rossetti LC, Abelleyro MM, et al. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation. J Thromb Haemost. 2015;13(4):530-539.
  13. Jeanne M, Piquet Y, Ivanovic Z, Vezon G, Salmi LR. Variations of factor VIII: C plasma levels with respect to the blood group ABO. Transfus Med. 2004;14(2):187-188.
  14. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA. 2011;306(6):627-636.
  15. D‚Aversa E, Breveglieri G, Pellegatti P, Guerra G, Gambari R, Borgatti M. Non-invasive fetal sex diagnosis in plasma of early weeks pregnants using droplet digital PCR. Mol Med. 2018;24(1):14.
  16. Mahdavi S, Karami F, Sabbaghi S. Non-invasive prenatal diagnosis of foetal gender through maternal circulation in first trimester of pregnancy. J Obstet Gynaecol. 2019;39(8):1071-1074.
  17. Belvini D, Salviato R, Acquila M, et al. Prenatal diagnosis of haemophilia B: the Italian experience. Haemophilia. 2013;19(6):898-903.
  18. Chuansumrit A, Sasanakul W, Promsonthi P, et al. Prenatal diagnosis for haemophilia: the Thai experience. H aemophilia. 2016;22(6):880-885.
  19. Cutler J, Chappell LC, Kyle P, Madan B. Third trimester amniocentesis for diagnosis of inherited bleeding disorders prior to delivery. Haemophilia. 2013;19(6):904-907.
  20. Zarrilli F, Sanna V, Ingino R, et al. Prenatal diagnosis of haemophilia: our experience of 44 cases. Clin Chem Lab Med. 2013;51(12):2233-2238.
  21. Lavery S. Preimplantation genetic diagnosis of haemophilia. Br J Haematol. 2009;144(3):303-307.
  22. Chen M, Chang SP, Ma GC, et al. Preimplantation genetic diagnosis of hemophilia A. Thromb J. 2016;14(Suppl 1):33.
  23. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922-2934.
  24. Astermark J, Donfield SM, Gomperts ED, et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 2013;121(8):1446-1454.
  25. Bachelet D, Albert T, Mbogning C, et al. Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS ONE. 2019;14(6):e0218258.
  26. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954-1962.
  27. Lochan A, Macaulay S, Chen WC, Mahlangu JN, Krause A. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014;20(5):687-692.
  28. Luna-Zaizar H, Gonzalez-Alcazar JA, Evangelista-Castro N, et al. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A: concordance analysis and literature review. Blood Cells Mol Dis. 2018;71:45-52.
  29. Miller CH, Benson J, Ellingsen D, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ ethnicity. Haemophilia. 2012;18(3):375-382.
  30. Radic CP, Rossetti LC, Abelleyro MM, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost. 2013;109(1):24-33.
  31. Rosset C, Gorziza RP, Botton MR, Salzano FM, Bandinelli E. Factor VIII mutations and inhibitor formation in a southern Brazilian population. Blood Coagul Fibrinolysis. 2014;25(2):125-127.
  32. Saini S, Hamasaki-Katagiri N, Pandey GS, et al. Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia
    B. Haemophilia. 2015;21(2):210-218.
  33. Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost. 2013;109(3):464-470.
  34. Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009;7(11):1809-1815.
  35. Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia
    A. Nat Genet. 1993;5(3):236-241.
  36. Naylor J, Brinke A, Hassock S, Green PM, Giannelli F. Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. Hum Mol Genet. 1993;2(11):1773-1778.
  37. Rossiter JP, Young M, Kimberland ML, et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet. 1994;3(7):1035-1039.
  38. Naylor JA, Buck D, Green P, Williamson H, Bentley D, Giannelli F. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions. H um Mol Genet. 1995;4(7):1217-1224.
  39. Tizzano EF, Domenech M, Baiget M. Inversion of intron 22 in isolated cases of severe hemophilia A. Thromb Haemost. 1995;73(1):6-9.
  40. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86(6):2206-2212.
  41. Albanez S, Ruiz-Saez A, Boadas A, de Bosch N, Porco A. Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations. Haemophilia. 2011;17(5):e913-e918.
  42. Dakhil AS, Al-Hajjiah NN, Shlash RF. Identification of factor VIII gene mutations in patients with haemophilia A. Int J Res Pharm Sci. 2018;9(2):274-283.
  43. Yunis LK, Linares A, Cabrera E, Yunis JJ. Systematic molecular analysis of hemophilia A patients from Colombia. Genet Mol Biol. 2018;41(4):750-757.
  44. Riccardi F, Tagliaferri A, Martorana D, et al. Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: identification of 23 new mutations. Haemophilia. 2010;16(5):791-800.
  45. Schroder J, El-Maarri O, Schwaab R, Muller CR, Oldenburg J. Factor VIII intron-1 inversion: frequency and inhibitor prevalence. J Thromb Haemost. 2006;4(5):1141-1143.
  46. Edison E, Konkle BA, Goodeve AC. Genetic analysis of bleeding disorders. Haemophilia. 2016;22(Suppl 5):79-83.
  47. Jenkins PV, Collins PW, Goldman E, et al. Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. Blood. 1994;84(7):2197-2201.
  48. Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92(4):1458-1459.
  49. Bagnall RD, Giannelli F, Green PM. Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection. J Thromb Haemost. 2006;4(3):591-598.
  50. Rossetti LC, Radic CP, Larripa IB, De Brasi CD. Developing a new generation of tests for genotyping hemophilia-c ausative rearrangements involving int22h and int1h hotspots in the factor VIII gene. J Thromb Haemost. 2008;6(5):830-836.
  51. Abelleyro MM, Rossetti LC, Curto Mde L, Radic CP, Marchione VD, De Brasi CD. F8 intron 22 inversions and SNP rs73563631 in unrelated families with severe haemophilia A: clinical features and gene testing implications. Thromb Haemost. 2016;115(3):678-681.
  52. Ding Q, Wu X, Lu Y, et al. AccuCopy quantification combined with pre-amplification of long-distance PCR for fast analysis of intron 22 inversion in haemophilia A. Clin Chim Acta. 2016;458:78-83.
  53. Hudecova I, Jiang P, Davies J, Lo YMD, Kadir RA, Chiu RWK. Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers. Blood. 2017;130(3):340-347.
  54. Pan TY, Chiou SS, Wang CC, Wu SM. Separation of intron 22 inversion type 1 and 2 of hemophilia A by modified inverse-shifting polymerase chain reaction and capillary gel electrophoresis. Talanta. 2014;130:328-335.
  55. Kumar P, Husain N, Soni P, Faridi NJ, Goel SK. New protocol for detection of intron 22 inversion mutation from cases with hemophilia A. Clin Appl Thromb Hemost. 2015;21(3):255-259.
  56. Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99(1):168-174.
  57. Al-Allaf FA, Abduljaleel Z, Bogari NM, et al. Identification of six novel factor VIII gene variants using next generation sequencing and molecular dynamics simulation. Acta Biochim Pol. 2019;66(1):23-31.
  58. Al-Allaf FA, Taher MM, Abduljaleel Z, et al. Molecular analysis of factor VIII and factor IX genes in hemophilia patients: identification of novel mutations and molecular dynamics studies. J Clin Med Res. 2017;9(4):317-331.
  59. Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC. Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol. 2014;89(4):375-379.
  60. Lyu C, Xue F, Liu X, et al. Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high- throughput sequencing. Haemophilia. 2016;22(5):e427-e434.
  61. Manderstedt E, Nilsson R, Lind-Hallden C, Ljung R, Astermark J, Hallden C. Targeted re-sequencing of F8, F9 and VWF: characterization of Ion Torrent data and clinical implications for mutation screening. PLoS ONE. 2019;14(4):e0216179.
  62. Salviato R, Belvini D, Radossi P, Tagariello G. High resolution melting for F9 gene mutation analysis in patients with haemophilia B. Blood Transfus. 2019;17(1):72-82.
  63. Rossetti LC, Goodeve A, Larripa IB, De Brasi CD. Homeologous recombination between AluSx-sequences as a cause of hemophilia. Hum Mutat. 2004;24(5):440.
  64. Payne AB, Bean CJ, Hooper WC, Miller CH. Utility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening. J Thromb Haemost. 2012;10(9):1951-1954.
  65. Costa C, Jouannic JM, Stieltjes N, Costa JM, Girodon E, Goossens M. Quantitative real-time PCR assay for rapid identification of deletion carriers in hemophilia. Clin Chem. 2004;50(7):1269-1270.
  66. Belvini D, Salviato R, Radossi P, Tagariello G. Multiplex ligationdependent probe amplification as first mutation screening for large deletions and duplications in haemophilia. H aemophilia. 2017;23(2):e124-e132.
  67. Konkle BA, Johnsen JM, Wheeler M, Watson C, Skinner M, Pierce GF. Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project. Haemophilia. 2018;24(Suppl 6):87-94.
  68. You GL, Ding QL, Lu YL, et al. Characterization of large deletions in the F8 gene using multiple competitive amplification and the genome walking technique. J Thromb Haemost. 2013;11(6):1103-1110.
  69. Wu X, Lu Y, Ding Q, et al. Characterisation of large F9 deletions in seven unrelated patients with severe haemophilia B. Thromb Haemost. 2014;112(3):459-465.
  70. Fernandez-Lopez O, Garcia-Lozano JR, Nunez-Vazquez R, Perez- Garrido R, Nunez-Roldan A. Characterization of sequence breakpoints in two haemophiliac patients with large FVIII gene deletions. Haemophilia. 2007;13(5):682-684.
  71. Tizzano EF, Barcelo MJ, Baena M, et al. Rapid identification of female haemophilia A carriers with deletions in the factor VIII gene by quantitative real-time PCR analysis. Thromb Haemost. 2005;94(3):661-664.
  72. Johnsen JM, Fletcher SN, Huston H, et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv. 2017;1(13):824-834.
  73. Sharifi Z, Rahiminejad F, Joudaki A, et al. Development and validation of a novel panel of 16 STR markers for simultaneous diagnosis of beta-thalassemia, aneuploidy screening, maternal cell contamination detection and fetal sample authenticity in PND and PGD/PGS cases. Sci Rep. 2019;9(1):7452.
  74. Allen S, Mountford R, Butler A, Mann K, Treacy B, Association for Clinical Genomic Science. Practice guidelines for the testing for maternal cell contamination (MCC) in prenatal samples for molecular studies. 2008. https://www.acgs.uk.com/quality/best-practice-guidelines/. Hozzáférés: 2020. február 12.
  75. Schrijver I, Cherny SC, Zehnder JL. Testing for maternal cell contamination in prenatal samples: a comprehensive survey of current diagnostic practices in 35 molecular diagnostic laboratories. J Mol Diagn. 2007;9(3):394-400.
  76. Nagan N, Faulkner NE, Curtis C, Schrijver I, MCC Guidelines Working Group of the Association for Molecular Pathology Clinical Practice Committee. Laboratory guidelines for detection, interpretation, and reporting of maternal cell contamination in prenatal analyses
    a report of the association for molecular pathology. J Mol Diagn. 2011;13(1):7-11.
  77. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
  78. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564-569.
  79. Claustres M, Kozich V, Dequeker E, et al. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet. 2014;22(2):160-170.
  80. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-747.
  81. Jourdy Y, Janin A, Fretigny M, et al. Recurrent F8 intronic deletion found in mild hemophilia A causes Alu exonization. Am J Hum Genet. 2018;102(2):199-206.
  82. Bach JE, Wolf B, Oldenburg J, Muller CR, Rost S. Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene. Thromb Haemost. 2015;114(4):757-767.
  83. Inaba H, Shinozawa K, Amano K, Fukutake K. Identification of deep intronic individual variants in patients with hemophilia A by next- generation sequencing of the whole factor VIII gene. Res Pract Thromb Haemost. 2017;1(2):264-274.
  84. Castaman G, Giacomelli SH, Mancuso ME, et al. Deep intronic variations may cause mild hemophilia A. J Thromb Haemost. 2011;9(8):1541-1548.
  85. Chang CY, Perng CL, Cheng SN, et al. Deep intronic variant c.5999- 277G>A of F8 gene may be a hot spot mutation for mild hemophilia A patients without mutation in exonic DNA. Eur J Haematol. 2019;103(1):47-55.
  86. Jourdy Y, Fretigny M, Lassalle F, Lillicrap D, Negrier C, Vinciguerra C. The highly prevalent deletions in F8 intron 13 found in French mild hemophilia A patients result from both founder effect and recurrent de novo events. J Thromb Haemost. 2020;18:1087-1093.
  87. Simeoni I, Stephens JC, Hu F, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 2016;127(23):2791-2803.
  88. Bastida JM, Gonzalez-Porras JR, Jimenez C, et al. Application of a molecular diagnostic algorithm for haemophilia A and B using next- generation sequencing of entire F8, F9 and VWF genes. Thromb Haemost. 2017;117(1):66-74.
  89. Sun P, Ma L, Diao G, Li CQ, Lin FZ. Application of indirect linkage analysis and direct genotyping to hemophilia A carrier detection in Sichuan, China. Genet Mol Res. 2015;14(3):8229-8235.
  90. Jourdy Y, Chatron N, Carage ML, et al. Study of six patients with complete F9 deletion characterized by cytogenetic microarray: role of the SOX3 gene in intellectual disability. J Thromb Haemost. 2016;14(10):1988-1993.
  91. Jourdy Y, Chatron N, Fretigny M, et al. Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling. Haemophilia. 2017;23(4):e316-e323.
  92. Janczar S, Kosinska J, Ploski R, et al. Haemophilia A and cardiovascular morbidity in a female SHAM syndrome carrier due to skewed X chromosome inactivation. Eur J Med Genet. 2016;59(1):43-47.
  93. Lannoy N, Hermans C. Review of molecular mechanisms at distal Xq28 leading to balanced or unbalanced genomic rearrangements and their phenotypic impacts on hemophilia. Haemophilia. 2018;24(5):711-719.
  94. Sarachana T, Dahiya N, Simhadri VL, et al. Small ncRNA expression-profiling of blood from hemophilia A patients identifies miR-1246 as a potential regulator of factor 8 gene. PLoS ONE. 2015;10(7):e0132433.
  95. Rosset C, Vieira IA, Salzano FM, Bandinelli E. A germline variant affects putative miRNA-binding sites at the F8 3’UTR and acts as a potential haemophilia A phenotype modifier in Southern Brazilian patients. Haemophilia. 2016;22(4):e327-e329.
  96. Jankowska KI, McGill J, Pezeshkpoor B, Oldenburg J, Atreya CD, Sauna ZE. Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs. Transfusion. 2020;60:401-413.
  97. Leuer M, Oldenburg J, Lavergne JM, et al. Somatic mosaicism in hemophilia A: a fairly common event. A m J Hum Genet. 2001;69(1):75-87.
  98. Kasper CK, Buzin CH. Mosaics and haemophilia. Haemophilia. 2009;15(6):1181-1186.
  99. Spreafico M, Peyvandi F. Combined FV and FVIII deficiency. Haemophilia. 2008;14(6):1201-1208.
  100. Boylan B, Rice AS, De Staercke C, et al. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. J Thromb Haemost. 2015;13(6):1036-1042.
  101. Nisen PD, Waber PG. Nonrandom X chromosome DNA methylation patterns in hemophiliac females. J Clin Invest. 1989;83(4):1400-1403.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.